Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
CytoMed Therapeutics Limited ( (GDTC) ) has provided an update.
On January 28, 2026, CytoMed Therapeutics issued a statement refuting what it described as inaccurate and misleading public claims about its research programs, clinical progress and operations, asserting that some of these assertions were taken out of context and aimed at influencing its share price. The company clarified that its core research centers on CAR γδ T cell therapies and iPSC-derived γδ NKT cell therapies, confirmed that its lead CAR γδ T cell program has regulatory approval and is already in a first-in-human clinical trial at Singapore’s National University Hospital, and emphasized that its other candidates remain in preclinical stages and are not approved for commercial use, underscoring its commitment to regulatory compliance, scientific rigor, transparent disclosure and potential action against dissemination of false information affecting its stakeholders.
The most recent analyst rating on (GDTC) stock is a Hold with a $0.85 price target. To see the full list of analyst forecasts on CytoMed Therapeutics Limited stock, see the GDTC Stock Forecast page.
Spark’s Take on GDTC Stock
According to Spark, TipRanks’ AI Analyst, GDTC is a Neutral.
The score is driven primarily by weak financial performance (sharp revenue decline, sizable net losses, and negative free cash flow), reinforced by bearish technicals (price below major moving averages and negative MACD). Valuation is not supportive because the negative P/E reflects ongoing losses and there is no dividend yield data.
To see Spark’s full report on GDTC stock, click here.
More about CytoMed Therapeutics Limited
CytoMed Therapeutics Limited is a Singapore-based, clinical-stage biopharmaceutical company spun out of the Agency for Science, Technology and Research (A*STAR) in 2018. It develops allogeneic, donor-derived cell-based immunotherapies for a broad range of cancers, leveraging proprietary gamma delta T cell and iPSC-derived gamma delta natural killer T cell technologies to create more affordable treatments for both hematological malignancies and solid tumors.
Average Trading Volume: 71,095
Technical Sentiment Signal: Sell
Current Market Cap: $10.44M
For an in-depth examination of GDTC stock, go to TipRanks’ Overview page.